2nd Symposium Targeted Cancer Therapy
November 19 - 20, 2012, DKFZ Heidelberg, Communication Center
Breakthroughs in cancer research within the last decade have revolutionised our understanding of the molecular pathology of cancer. Nevertheless, the success of most of the currently available targeted cancer therapies is limited and the development of novel treatment options is slow. To accelerate the translation of research findings to novel therapeutics, the German Cancer Research Center (DKFZ) and Bayer HealthCare have joined forces and set up a strategic Alliance in 2008.
The Symposium is held within the framework of this partnership and is jointly organized by the DKFZ and Bayer HealthCare. It is the second of its kind and will bring together preclinical and clinical scientists to present their recent research findings relevant to the identification of novel targets or the development of novel therapeutic strategies.
The goal is to discuss established and emerging targeted cancer therapies. Scientific and clinical aspects will be reviewed in the context of oncogenomics, cancer stem cells, and immunotherapy. We cordially invite you to the stimulating environment and “scientific hot spot” of Heidelberg to discuss with us options to translate scientific ideas to novel treatment options.
Scientific Organizing Committee:
Philipp Beckhove, DKFZ. Volker Gekeler, BHC. Christof von Kalle, DKFZ, NCT. Bertolt Kreft, BHC. Peter Lichter, DKFZ. Dominik Mumberg, BHC. Andreas Trumpp, DKFZ. Otmar D. Wiestler, DKFZ. Karl Ziegelbauer, BHC.